Literature DB >> 1378891

A study of adhesion molecules as markers of progression in malignant melanoma.

K J Denton1, J R Stretch, K C Gatter, A L Harris.   

Abstract

Adhesion molecules are substances which are involved in the interactions between cells, and between cells and the extracellular matrix in both benign and malignant tissues. Two members of this group--intercellular adhesion molecule-1 (ICAM-1) and MUC18--have previously been found to be expressed on melanoma; however, studies seeking a correlation between expression and metastatic behaviour have yielded conflicting results. In this study we investigated the expression of these two antigens and that of a number of other adhesion molecules [VCAM-1, ELAM, and the neural cell adhesion molecule (NCAM)] on a range of benign and malignant melanocytic lesions. Both ICAM-1 and MUC18 were found on a high percentage of all melanocytic lesions including benign naevi. VCAM-1 was found to be expressed on 79 per cent of benign naevi, 62 per cent of primary melanomas less than 1.5 mm in depth, and 6 per cent of thick primaries. The antigen was present on 14 per cent of lymph node metastases and on no extranodal deposits. This suggests that loss of melanoma cell adhesion mediated by VCAM-1 may be important in the development of metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378891     DOI: 10.1002/path.1711670205

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells.

Authors:  Haibo Qiu; Yinsheng Wang
Journal:  J Proteome Res       Date:  2008-04-15       Impact factor: 4.466

2.  Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

Authors:  D S Sanders; K Blessing; G A Hassan; R Bruton; J R Marsden; J Jankowski
Journal:  Mol Pathol       Date:  1999-06

Review 3.  Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.

Authors:  K S Nair; R Naidoo; R Chetty
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

4.  Neural cell adhesion molecule potentiates the growth of murine melanoma via β-catenin signaling by association with fibroblast growth factor receptor and glycogen synthase kinase-3β.

Authors:  Rui Liu; Yu Shi; Hai Jie Yang; Lei Wang; Si Zhang; Yin Yan Xia; Jing Lin Jack Wong; Zhi Wei Feng
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

5.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

6.  PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).

Authors:  Sandra Medic; Mel Ziman
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

7.  Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.

Authors:  Scott Bidlingmaier; Jiang He; Yong Wang; Feng An; Jinjin Feng; Dario Barbone; Dongwei Gao; Ben Franc; V Courtney Broaddus; Bin Liu
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

8.  Expression and distribution of MUC18 in human uveal melanoma.

Authors:  Kenneth Lai; Vidushi Sharma; Martine J Jager; R Max Conway; Michele C Madigan
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

9.  The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium.

Authors:  S B Fox; G D Turner; R D Leek; R M Whitehouse; K C Gatter; A L Harris
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Targeting of liposomes via PSGL1 for enhanced tumor accumulation.

Authors:  Robert Carlisle; Leonard W Seymour; Constantin C Coussios
Journal:  Pharm Res       Date:  2012-09-20       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.